GlassScriptPhysician profile
Anupa Mandava
NPI 1710257316
$1,370.79
in general payments reported to CMS, 2019-2025
15 companies · $31.84 in 2025
The $31.84 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $262 · 2021: $322 · 2022: $16.57 · 2023: $46.56 · 2024: $240 · 2025: $31.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.24 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $320.17 | 2019-2024 | Yutiq, Iluvien |
| Regeneron Healthcare Solutions, INC. | $214.85 | 2019-2023 | Eylea |
| Astellas Pharma US INC | $151.47 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $129.36 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $116.53 | 2021 | |
| Regeneron Pharmaceuticals, INC. | $113.40 | 2019 | |
| Genentech USA, INC. | $95.84 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $48.42 | 2022-2024 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.22 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $36.57 | 2021 | |
| Sun Pharmaceutical Industries INC. | $26.88 | 2020 | |
| Allergan, INC. | $24.25 | 2020 | |
| Abbvie INC. | $17.70 | 2025 | |
| Ivantis, INC | $15.99 | 2020 | |
| Spark Therapeutics, INC. | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupa Mandava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.